The progress in Q3’22/23 (Nov–Jan) continues to support the long term case we’re seeing in Qlucore, where the company aims to provide laboratories with its Diagnostics software to analyze complex data sets to enable a more individualized treatment, primarily for cancers. With Net Cash still above the current market cap we see limited downside in the valuation and maintain our fair value of 34-46 SEK in 12-24 months. After the first demonstration of a preliminary classification model for bladder cancer carried out during Q3, the next important step is now the announcement of a target date for the CE marking.
Johan Widmark | 2023-03-02 08:00
A soft quarter in line with plan and our forecast
While revenues in Q3’22/23 (Nov-Jan) were down 22% (after strong comparable with 50% growth same period previous year) to SEK 4.3m, in line with our forecast, Qlucore is on track to reach our forecast for the full year 2022/2023 of SEK 15m. As expected, revenues in the quarter consist almost entirely of the data analysis segment with Qlucore Omics Explorer. EBIT at SEK -2.9m was slightly stronger the SEK -5m loss we expected. Net cash now amounts to SEK 66m, marginally above the company’s market cap. After the Q3-report we’ve only made some minor upwards revisions to our EBIT forecast for the full year, and keep our long term forecast for 2023/24 and beyond unchanged.
Contract with Notified Body important milestone
In addition to Qlucore Omics Explorer, Qlucore provides two software packages for clinical RNA-seq data analyses to facilitate classification of cancer patients as well as detailed gene fusion analysis. Those are Qlucore Insights that is already available and used at several customer sites, but for research use only, and Qlucore Diagnostics which is under development and targeted for CE-IVDR compliance. The main news item in the Q3-report was that Qlucore now has a contract signed with a Notified Body for the certification of Qlucore Diagnostics according to IVDR (CE marking), which will be required for launch. Considering that access to Notified Bodies is constrained, this both confirms the maturity of the product and signifies an important milestone of the development schedule. Now the next important step we await is the announcement of a target date for the CE marking.
Share still trading below cash with considerable upside
Qlucore continues to invest heavily in the development of cancer diagnostics tool Qlucore Insights/Diagnostics. After the Q3’22 report, we maintain our base case of a CE approval for the Qlucore Diagnostics platform and ALL in 2024, with a subsequent increase in the number of labs to 70-100 labs by 2027/28. With an estimate of the number of tests per lab at 2,500-4,000 per year, and an estimated price per test of SEK 1,000, we find support for the company’s sales target of SEK 300m in 2027/28 and a 40% EBIT margin. Based on a combined DCF and multiple valuation we continue to find support for a fair value of SEK 34-46 in 12-24 months, leaving plenty of upside from today’s level. We now see a) progress on CE application and CE marking target date announcement, b) new license sales, and c) the first Diagnostics sales as the most important catalysts for the share.
DISCLAIMER
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research does not constitute investment advice and is not a solicitation to buy shares. Information provided here or on Emergers’ website emergers.se is not intended to be financial advice. This research shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers charges a standard fee for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers’ own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers’ policies on personal dealing and conflicts of interest.
Copyright: Copyright 2023 Incirrata AB (Emergers)
United Kingdom
This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Emergers relies upon the ”publishers’ exclusion” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
